Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Stephen Yiu Chuen Choi"'
Publikováno v:
BJUI Compass, Vol 4, Iss 3, Pp 256-265 (2023)
Abstract Background Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. We performed a systematic review and meta‐analysis to evaluate the prevalence of genomic alterations in NEPC and better understand its molecular featu
Externí odkaz:
https://doaj.org/article/6ad763676f84450aa2fdd56f3a854174
Autor:
Stephen Yiu Chuen Choi, Susan L. Ettinger, Dong Lin, Hui Xue, Xinpei Ci, Noushin Nabavi, Robert H. Bell, Fan Mo, Peter W. Gout, Neil E. Fleshner, Martin E. Gleave, Colin C. Collins, Yuzhuo Wang
Publikováno v:
Cancer Medicine, Vol 7, Iss 7, Pp 3385-3392 (2018)
Abstract Development of neuroendocrine prostate cancer (NEPC) is emerging as a major problem in clinical management of advanced prostate cancer (PCa). As increasingly potent androgen receptor (AR)‐targeting antiandrogens are more widely used, PCa t
Externí odkaz:
https://doaj.org/article/09ea5c152b8e444ebb50c29d8fcb55e0
Autor:
Jodi Wong, Stephen Yiu Chuen Choi, Rongrong Liu, Eddie Xu, James Killam, Peter W. Gout, Yuzhuo Wang
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 9 (2019)
Many global infectious diseases are not well-controlled, underlining a critical need for new, more effective therapies. Pathogens and pathogen-infected host cells, like cancer cells, evade immune surveillance via immune evasion mechanisms. The presen
Externí odkaz:
https://doaj.org/article/6531244f7bd94fd5b1387c69a6c5ca1f
Publikováno v:
Asian Journal of Urology, Vol 3, Iss 4, Pp 195-202 (2016)
Prostate cancers (PCa) have been reported to actively suppress antitumor immune responses by creating an immune-suppressive microenvironment. There is mounting evidence that PCas may undergo an ‘‘Epithelial Immune Cell-like Transition’’ (EIT)
Externí odkaz:
https://doaj.org/article/eba8cdb4900f429fa2b5e1821b47e017
Autor:
Xinpei Ci, Jun Hao, Xin Dong, Hui Xue, Rebecca Wu, Stephen Yiu Chuen Choi, Anne M. Haegert, Colin C. Collins, Xuefeng Liu, Dong Lin, Yuzhuo Wang
Publikováno v:
Cells, Vol 9, Iss 6, p 1398 (2020)
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. It develops mainly via NE transdifferentiation of prostate adenocarcinoma in response to androgen receptor (AR)-inhibition therapy. The study of NEPC development has been h
Externí odkaz:
https://doaj.org/article/7436c77ec2594d198d945071ff0bf333
Autor:
Yuzhuo Wang, Peter W. Gout, Martin E. Gleave, Colin C. Collins, Dong Lin, Ladan Fazli, Rebecca Wu, Hui Xue, Stephen Yiu Chuen Choi
List of Antisense Oligonucleotides (ASOs) and qPCR Primer Sequences used.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2df3486d29842d56fd660077a5a902f7
https://doi.org/10.1158/1078-0432.22457349.v1
https://doi.org/10.1158/1078-0432.22457349.v1
Autor:
Yuzhuo Wang, Peter W. Gout, Martin E. Gleave, Colin C. Collins, Dong Lin, Ladan Fazli, Rebecca Wu, Hui Xue, Stephen Yiu Chuen Choi
Candidate MCT4-targeting ASOs are able to inhibit cell proliferation and MCT4 expression of LNCaP human prostate cancer cells 48 hours after transfection. A) MCT4 ASOs are able to inhibit LNCaP cell proliferation to levels comparable to those observe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb7daea108e0cb05f5457001dc8f1ef
https://doi.org/10.1158/1078-0432.22457358
https://doi.org/10.1158/1078-0432.22457358
Autor:
Yuzhuo Wang, Peter W. Gout, Martin E. Gleave, Colin C. Collins, Dong Lin, Ladan Fazli, Rebecca Wu, Hui Xue, Stephen Yiu Chuen Choi
Purpose: The management of castration-resistant prostate cancer (CRPC) is a major challenge in the clinic. Androgen receptor signaling–directed strategies are not curative in CRPC therapy, and new strategies targeting alternative, key cancer proper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9af2d207ae1bbd0f50093d73f3a7ce07
https://doi.org/10.1158/1078-0432.c.6523560.v1
https://doi.org/10.1158/1078-0432.c.6523560.v1
Publikováno v:
Nature Reviews Urology. 18:581-596
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises de novo only rarely; the disease predominantly develops from adenocarcinoma in response to drug-induced androgen receptor signalling inhibition, although the me
Autor:
Haiqing He, Colin Collins, Jun Hao, Yuzhuo Wang, Xinpei Ci, Stephen Yiu Chuen Choi, Yu Wang, Hui Xue, Mingchen Shi, Sifeng Qu, Yong Wang, Dong Lin, Xiaokun Zhao, Rebecca Wu, Xin Dong
Publikováno v:
Prostate Cancer and Prostatic Diseases
Background Androgen deprivation therapy (ADT) remains the leading systemic therapy for locally advanced and metastatic prostate cancers (PCa). While a majority of PCa patients initially respond to ADT, the durability of response is variable and most